What’s behind the whopping price tags on the newest generation of drugs
August 18th, 2008
Seattle Times
READ MORE
Latest Developments
Teaching Congress a Thing (or Ten)
August 18th, 2008
Genome Technology Online
READ MORE
Insmed Lands Front Page Story in WaPo
August 14th, 2008
Virginia Bioscience Blog
READ MORE
Congressional Fact-finding on Follow-on Biologics
August 14th, 2008
Patent Docs
READ MORE
Does Congress Need A Lesson On Biotechnology or Economics?
August 14th, 2008
Patent Baristas
READ MORE
Insmed’s Follow-on Biologics Campaign Continues
August 14th, 2008
Patent Docs
READ MORE
Biotech Campaigns for Easier Access to Generic Drug Market
August 13th, 2008
Washington Post
READ MORE
Dr Reddy`s to form JV for off-patent drugs
July 29th, 2008
Business Standard
READ MORE
Roche-Genentech: A Defensive Play on Follow-On Biologics
July 29th, 2008
The RPM Report
READ MORE
Congress Probes Price Hikes of Older Rare Disease Drugs
July 28th, 2008
BioWorld Today
READ MORE
Lawmakers Lambaste Drugmakers for ‘Egregious’ Prices
July 28th, 2008
FDA News
READ MORE
He’s Back: Thomas Wades Unabashedly Into Biogenerics Debate
July 28th, 2008
CQ
READ MORE
Neupogen Biosimilar Shows Good Results in Study
July 24th, 2008
FDA News
READ MORE
Washington Strongman to Advise Insmed
July 24th, 2008
BioWorld Today
READ MORE
Insmed Announces Partnership With Former House Ways and Means Chairman
July 24th, 2008
Patent Docs
READ MORE
Former congressman joins Insmed as adviser
July 24th, 2008
Richmond Times-Dispatch
READ MORE
The Enemies You Keep
July 24th, 2008
In Vivo Blog
READ MORE
Insmed retains adviser to explore prospects
July 15th, 2008
Richmond Times-Dispatch
READ MORE
Biotech Company Plans Clinical Trial on Follow-on Cancer Biologic
July 15th, 2008
CQ
READ MORE
Insmed copies Amgen’s Neupogen but FDA likely to wait for biogeneric pathway before approving the drug
July 14th, 2008
Financial Times
READ MORE
Insmed’s Biogeneric Deemed Equal To Neupogen
July 11th, 2008
The Pink Sheet
READ MORE
Health Winners & Losers: Insmed
July 11th, 2008
TheStreet.com
READ MORE
Insmed: Neupogen Biosimilar Shows Promising Results in Trial
July 11th, 2008
FDA News
READ MORE
Insmed drug shows equivalence to Amgen’s Neupogen
July 10th, 2008
Reuters
READ MORE
Insmed Develops Biologic For Amgen’s Neupogen
July 10th, 2008
Pharmalot
READ MORE
The U.S. Senate and House of Representatives are both considering legislation that would authorize the US Food and Drug Administration (Rockville, MD) to approve follow-on biologics.
In December of 2007, the House Committee on Energy and Commerce Subcommittee on Health asked its Members to submit questions to be responded to by various stakeholders regarding follow-on biologics legislation.
--Check this page for future updates on the establishment of a follow-on biologics approval pathway.--
-
Press Releases
Archives
